Endocannabinoids: New Physiological (Co-)Agonists of Human Platelets
- 1 January 2002
- journal article
- letter
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 88 (07) , 165-166
- https://doi.org/10.1055/s-0037-1613175
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Endocannabinoid Degradation, Endotoxic Shock and InflammationCurrent Drug Targets - Inflammation & Allergy, 2002
- Activation of PAF receptors results in enhanced synthesis of 2‐arachidonoylglycerol (2‐AG) in immune cellsThe FASEB Journal, 2001
- Lipopolysaccharide Downregulates Fatty Acid Amide Hydrolase Expression and Increases Anandamide Levels in Human Peripheral LymphocytesArchives of Biochemistry and Biophysics, 2001
- 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB 1 receptorProceedings of the National Academy of Sciences, 2001
- Human platelets bind and degrade 2‐arachidonoylglycerol, which activates these cells through a cannabinoid receptorEuropean Journal of Biochemistry, 2001
- Cytoskeletal Proteins and Platelet SignalingThrombosis and Haemostasis, 2001
- Cellular signal transduction by anandamide and 2-arachidonoylglycerolChemistry and Physics of Lipids, 2000
- Platelet activation: a new vascular activity of anandamideFEBS Letters, 2000
- Activation of rabbit blood platelets by anandamide through its cleavage into arachidonic acidFEBS Letters, 2000
- A dual thrombin receptor system for platelet activationNature, 1998